Browse > Article

Industrial-Scale Production of High-Purity Antihemophilic Factor IX from Human Plasma  

Kang, Yong (Central Research Center, Green Cross Corp.)
Choi, Yong-Woon (Central Research Center, Green Cross Corp.)
Sung, Hark-Mo (Central Research Center, Green Cross Corp.)
Sohn, Ki-Whan (Central Research Center, Green Cross Corp.)
Shin, Jeong-Sup (Central Research Center, Green Cross Corp.)
Kim, In-Seop (Department of Biological Sciences, College of Life Science and Nanotechnology, Hannam University)
Publication Information
KSBB Journal / v.23, no.1, 2008 , pp. 37-43 More about this Journal
Abstract
The use of antihemophilic factor IX complex has been associated with a variety of thrombotic complications, the major cause of which was the contamination of thrombogenic proteins such as vitamin K-dependent clotting factors II, VII, and X. In order to produce a commercial factor IX (GreenNine VF) free from thrombogenic potential, industrial-scale production process for high-purity factor IX from human plasma has been developed. The purification process contains cryo-precipitation, DEAE-sephadex A-50 anion-exchange chromatography, DEAE-toyopearl 650M anion-exchange column chromatography, heparin-sepharose 6FF affinity column chromatography, and CM-sepharose FF cation-exchange column chromatography. Also the process includes two viral inactivation and removal procedures, solvent/detergent treatment and nanofiltration using Viresolve NFP filter. The purification yield was 35.4%. The specific activity in the purified concentrate was 190.8 IU/mg which exceeded that in the factor IX complex (FacNine) by a factor of 48. The activities of factor II, VII, and X were not detected in GreenNine VF. SDS-PAGE analysis showed that GreenNine VF had the highest purity in comparison with commercially available high purity factor IX concentrates, Mononine, Octanyne, Berinin HS, and Immunine STIM plus 600. One batch size of the production was 2,400 vials of 250 IU product or 1,200 vials of 500 IU product from 1,600 L cryo-poor plasma.
Keywords
high purity antihemophilic factor IX; chromatography; vitamin K-dependent clotting factors; industrial-scale production;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 O'Connell, N. M. (2003), Factor XI deficiency-from molecular genetics to clinical management, Blood Coagul. Fibrinolysis 14(Suppl 1), 59-64   DOI
2 Lusher, J. M. (1991), Tnrombogenicity associated with factor IX complex concentrates, Semin. Hematol. 28(suppl 6), 3-5
3 Kim, I. S., Y. W. Choi, S. R. Lee, and H. M. Sung (2004), Cold ethanol fractionation and heat inactivation of hepatitis A virus during manufacture of albumin from human plasma, Biotechnol. Bioprocess Eng. 9, 57-60
4 Kim, I. S., Y. W. Choi, H. S. Woo, C. E. Chang, and S. Lee (2000), Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor VllI concentrate, J. Microbiol. 38, 187-191
5 Valentino, L. A. and V. M. Oza (2006), Blood safety and the choice of anti-hemophilic factor concentrate, Pedatr. Blood Cancer 47, 245-254   DOI   ScienceOn
6 Schneider, B., M. Becker, H. H. Brackman, and A. M. Eis-Hubinger (2004), Contantination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2, Thromb. Haemost. 92, 838-845
7 Grinde, B., K. Stene-Johansen, B. Sharma, T. Hoel, M. Jensenius, and K. Skaug (1997), Characterization of an epidemic of hepatitis A virus involving intravenous drug abusers-infection by needle sharing?, J. Med. Virol. 53, 69-75   DOI   ScienceOn
8 Hoots, W. K. (2001), Safety issues affecting hemophilia products, Transfus. Med. Rev. 15(Suppl 1), 11-19   DOI   ScienceOn
9 Berkman, S. A. (1988), Infectious complications of blood transfusion, Blood Rev. 2, 206-210   DOI   ScienceOn
10 Horowitz, M. S., C. Rooks, B. Horowitz, and M. W. Hilgartner (1986), Virus safety of solvent/detergent treated antihaemophiliac factor concentrates, Lancet 2, 186-189
11 Klein, H. G. (2005), Pathogen inactivation technology: cleansing the blood supply, J. Intern. Med. 257, 224-237   DOI   ScienceOn
12 Mosley, J. W. and J. Rakela (1999), Foundling viruses and transfusion medicine, Transfusion 39, 1041-1044   DOI   ScienceOn
13 Kim, I. S., Y. W. Choi, and S. R. Lee (2004), Optimization and validation of a virus filtration process for efficient removal of viruses from urokinase solution prepared from human urine, J. Microbiol. Biotechnol. 14, 140-147
14 Feldman, P. A., P. I. Bradbury, J. D. Williams, G. E. Sims, J. W. McPhee, M. A. Pinnell, L. Harris, G. I. Crombie, and D. R. Evans (1994), Large-scale preparation and biochemical characterization of a new high purity factor IX concentrate prepared by metal chelate affinity chromatography, Blood Coagul. Fibrinolysis 5, 939-948   DOI
15 Yee, T. T. and C. A. Lee (2005), Transfusion-transmitted infection in hemophilia in developing countries, Semin. Thromb. Hemost. 31, 527-537   DOI   ScienceOn
16 Tagariello G, P. G. Davoli, G. B. Gajo, E. De Biasi, R. Risato, R. Baggio, and A. Traldi (1999), Safety and efficacy of high-purity concentrates in haemophiliac patients undergoing surgery by continuous infusion, Haemophilia. 5, 426-30   DOI   ScienceOn
17 Oshima, K. H., T. T. Evans-strickfaden, A. K. Highsmith, and E. W. Ades (1996), The use of a microporous polyvinylidene fluoride (PVDF) membrane filter to separate contaminating viral particles from biologically important proteins, Biologicals 24, 137-145   DOI   ScienceOn
18 Kasper , C. L. (1975), Clinical use of prothromb in complex concentrate: Report on thrombiembolic complications, Thromb. Diath. Haemorrh. 33, 640-644
19 Limentani, S. A., K. P. Gowell, and S. R. Deitcher (1995), High-purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potential, Acta Haematol. 94(suppl 1), 12-17   DOI
20 Suomela, H. (1976), Human coagulation factor IX isolation and characterization, Eur. J. Biochem. 71, 145-154   DOI   ScienceOn
21 World Federation of Hemophilia. (2004), Registry of clotting factor concentrates
22 Shin, J. S., Y. W. Choi, H. M. Sung, Y. -W. Ryu, and I. S. Kim (2006), Enhanced virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate by dry-heat treatment, Biotechnol. Bioprocess Eng. 11, 19-25   과학기술학회마을   DOI
23 Kohler, M., P. Hellstern, E. Lechler, P. Uberfuhr, and G. Muller-Berghaus (1998), Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates, Thrombo. Haemost. 80, 399-402   DOI
24 Lambert, T., M. Recht, L. A. Valentino, J. S. Powell, C. Udata, S. T. Sullivan, and D. A. Roth (2007), Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B, Haemophilia. 13, 233-243   DOI   ScienceOn
25 Roberts, P. (1996), Virus safety of plasma products, Rev. Med. Virol. 6, 25-38   DOI   ScienceOn
26 Bradford, M. M. (1976), A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem. 72, 248-254   DOI   ScienceOn
27 Burnouf, T. and M. Radosevich (2003), Nanofiltration of plasma-derived biopharmaceutical products, Haemophilia. 9, 24-37   DOI   ScienceOn
28 Kim, J. S., Y. W. Choi, S. R. Lee, Y. Kang, K. M. Lee, D. H. Park, H. S. Woo, and S. Lee (2002), Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 7, 340-346   DOI   ScienceOn